Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Research Tools
Calendars
Economic Indicators
Calculators
Education
About Us
Working with TipRanks
Follow Us
EyePoint Pharmaceuticals Inc (EYPT)
NASDAQ:EYPT
RESEARCH TOOLSreports
EyePoint Pharmaceuticals (EYPT) Stock Price & Analysis
723 Followers
EYPT Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$5.67 - $30.99
Previous Close$16.75
Volume957.49K
Average Volume (3M)980.19K
Market Cap
$834.67M
Enterprise Value$703.82M
Total Cash (Recent Filing)$136.03M
Total Debt (Recent Filing)$5.18M
Price to Earnings (P/E)-9.1
Beta1.77
Next Earnings
May 01, 2024EPS Estimate
-$0.41Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.84
Shares Outstanding49,830,792
10 Day Avg. Volume1,296,708
30 Day Avg. Volume980,191
Standard Deviation0.44
R-Squared0.04
Alpha0.04
Financial Highlights & Ratios
Price to Book (P/B)14.24
Price to Sales (P/S)21.22
Price to Cash Flow (P/CF)-13.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue18.19
Enterprise Value/Gross Profit17.00
Enterprise Value/Ebitda-14.33
Forecast
1Y Price Target
$38.50Price Target Upside118.75% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EyePoint Pharmaceuticals News
Bulls Say, Bears Say
Bulls Say
Clinical Development ProgressPositive Phase 2 data for EYP-1901/Duravyu in wet AMD strengthens confidence in the drug's efficacy and signifies a reduction in treatment burden, potentially leading to a best-in-class treatment option.
Financial Health And PerformanceEyePoint Pharmaceuticals reports a strong cash position, providing a solid financial runway for continued development and potential commercial success of its innovative treatment, EYP-1901/Duravyu.
Product PotentialEyePoint Pharmaceuticals' lead candidate EYP-1901/Duravyu shows promising potential to set a new standard of care in the treatment of severe eye diseases, with the ability to challenge frequent injection treatments.
Bears Say
Clinical Trial ResultsOn negative data from the PAVIA study, there is potential for asymmetric share downside due to negative implications for the original DAVIO 2 data.
Regulatory ChallengesJapan-related revenue removed from forecasts due to challenges in securing approval.
Stock PerformanceThe stock is down 60% from its recent high in August.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
EYPT FAQ
What was EyePoint Pharmaceuticals Inc’s price range in the past 12 months?
EyePoint Pharmaceuticals Inc lowest stock price was $5.67 and its highest was $30.99 in the past 12 months.
What is EyePoint Pharmaceuticals Inc’s market cap?
Currently, no data Available
When is EyePoint Pharmaceuticals Inc’s upcoming earnings report date?
EyePoint Pharmaceuticals Inc’s upcoming earnings report date is May 01, 2024 which is today.
How were EyePoint Pharmaceuticals Inc’s earnings last quarter?
EyePoint Pharmaceuticals Inc released its earnings results on Mar 07, 2024. The company reported -$0.33 earnings per share for the quarter, beating the consensus estimate of -$0.486 by $0.156.
Is EyePoint Pharmaceuticals Inc overvalued?
According to Wall Street analysts EyePoint Pharmaceuticals Inc’s price is currently Undervalued.
Does EyePoint Pharmaceuticals Inc pay dividends?
EyePoint Pharmaceuticals Inc does not currently pay dividends.
What is EyePoint Pharmaceuticals Inc’s EPS estimate?
EyePoint Pharmaceuticals Inc’s EPS estimate is -$0.41.
How many shares outstanding does EyePoint Pharmaceuticals Inc have?
EyePoint Pharmaceuticals Inc has 49,830,790 shares outstanding.
What happened to EyePoint Pharmaceuticals Inc’s price movement after its last earnings report?
EyePoint Pharmaceuticals Inc reported an EPS of -$0.33 in its last earnings report, beating expectations of -$0.486. Following the earnings report the stock price went down -1.671%.
Which hedge fund is a major shareholder of EyePoint Pharmaceuticals Inc?
Among the largest hedge funds holding EyePoint Pharmaceuticals Inc’s share is Perceptive Advisors LLC. It holds EyePoint Pharmaceuticals Inc’s shares valued at 14M.
---
EyePoint Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$38.50 (118.75% Upside)
$38.50 (118.75% Upside)
Blogger Sentiment
Bullish
EYPT Sentiment 71%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Decreased
By 2.0M Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $10.5M over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 0.3%
Last 30 Days ▼ 5.1%
Last 30 Days ▼ 5.1%
Technicals
SMA
Positive
20 days / 200 days
Momentum
180.73%
12-Months-Change
Fundamentals
Return on Equity
-39.04%
Trailing 12-Months
Asset Growth
96.93%
Trailing 12-Months
Company Description
EyePoint Pharmaceuticals Inc
EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in the development and commercializing of ophthalmic products. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.
---
EYPT Earnings Call
Q4 2024
0:00 / 0:00
---
EYPT Stock 12 Months Forecast
Average Price Target
$38.50
▲(118.75% Upside)
Technical Analysis
Best Analysts Covering EYPT
1 Year
1 Year Success Rate
6/8 ratings generated profit
1 Year Average Return
+77.99%
reiterated a buy rating 2 months ago
Copying Colleen M. Kusy's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +77.99% per trade.
---